National Cancer Institute Thesaurus

Last uploaded: May 28, 2019
Preferred Name

Trastuzumab

Synonyms

trastuzumab

ALT02

Trastuzumab-QYYP

Trastuzumab Biosimilar ABP 980

trastuzumab biosimilar EG12014

Trastuzumab Biosimilar PF-05280014

Anti-HER2/c-erbB2 Monoclonal Antibody

Trastuzumab-DTTB

MoAb HER2

Trazimera

Herceptin Trastuzumab Biosimilar PF-05280014

Trastuzumab-dkst

Anti-c-ERB-2

Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer

Trastuzumab Biosimilar ALT02

rhuMAb HER2

RO0452317

c-erb-2 Monoclonal Antibody

Trastuzumab Biosimilar HLX02

Monoclonal Antibody c-erb-2

Anti-erbB2 Monoclonal Antibody

Herceptin Biosimilar PF-05280014

TRASTUZUMAB

Ontruzant

Herceptin

HER2 Monoclonal Antibody

Anti-c-erbB2 Monoclonal Antibody

PF-05280014

Anti-ERB-2

Anti-erbB-2

Trastuzumab-pkrb

Ogivri

Anti-p185-HER2

Monoclonal Antibody HER2

ABP 980

Herzuma

Trastuzumab

Definitions

A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)

ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1647

Accepted_Therapeutic_Use_For

Breast cancer overexpressing HER2 protein; Pancreatic cancer overexpressing p185HER2

ALT_DEFINITION

A monoclonal antibody that binds to HER2 (human epidermal growth factor receptor 2), and can kill HER2-positive cancer cells. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Trastuzumab is used to treat breast cancer that is HER2-positive and has spread after treatment with other drugs. It is also used with other anticancer drugs to treat HER2-positive breast cancer after surgery. Trastuzumab is also being studied in the treatment of other types of cancer.

CAS_Registry

180288-69-1

code

C1647

Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

Contributing_Source

CTRP

FDA

DEFINITION

A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)

Display_Name

Trastuzumab

FDA_UNII_Code

P188ANX8CK

FULL_SYN

trastuzumab

ALT02

Trastuzumab-QYYP

Trastuzumab Biosimilar ABP 980

trastuzumab biosimilar EG12014

Trastuzumab Biosimilar PF-05280014

Anti-HER2/c-erbB2 Monoclonal Antibody

Trastuzumab-DTTB

MoAb HER2

Trazimera

Herceptin Trastuzumab Biosimilar PF-05280014

Trastuzumab-dkst

Anti-c-ERB-2

Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer

Trastuzumab Biosimilar ALT02

rhuMAb HER2

RO0452317

c-erb-2 Monoclonal Antibody

Trastuzumab Biosimilar HLX02

Monoclonal Antibody c-erb-2

Anti-erbB2 Monoclonal Antibody

Herceptin Biosimilar PF-05280014

TRASTUZUMAB

Ontruzant

Herceptin

HER2 Monoclonal Antibody

Anti-c-erbB2 Monoclonal Antibody

PF-05280014

Anti-ERB-2

Anti-erbB-2

Trastuzumab-pkrb

Ogivri

Anti-p185-HER2

Monoclonal Antibody HER2

ABP 980

Herzuma

Trastuzumab

Has_Target

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17319

label

Trastuzumab

Legacy_Concept_Name

Trastuzumab

NSC_Code

688097

PDQ_Closed_Trial_Search_ID

42265

PDQ_Open_Trial_Search_ID

42265

Preferred_Name

Trastuzumab

prefixIRI

ncit:C1647

Semantic_Type

Immunologic Factor

Amino Acid, Peptide, or Protein

UMLS_CUI

C0728747

subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155711

Delete Subject Author Type Created
No notes to display
Create New Mapping

Delete Mapping To Ontology Source
http://purl.bioontology.org/ontology/MESH/D000068878 MESH LOOM
http://purl.bioontology.org/ontology/RXNORM/224905 RXNORM LOOM
http://bmi.utah.edu/ontologies/hfontology/C0728747 HFO LOOM
http://purl.bioontology.org/ontology/UATC/L01XC03 ATC LOOM
http://purl.bioontology.org/ontology/VANDF/4021140 VANDF LOOM
http://www.drugbank.ca/drugs/DB00072 FTC LOOM
http://phenomebrowser.net/ontologies/mesh/mesh.owl#C112748 RH-MESH LOOM
http://purl.obolibrary.org/obo/DRON_00013025 ODNAE LOOM
http://purl.obolibrary.org/obo/DRON_00013025 DRON LOOM
http://evs.nci.nih.gov/ftp1/NDF-RT/NDF-RT.owl#N0000148593 ODAE LOOM
http://purl.obolibrary.org/obo/dinto_DB00072 DINTO LOOM
http://purl.jp/bio/4/id/200906019489166096 IOBC LOOM
http://d-nb.info/gnd/4661821-1 FAST-TOPICAL LOOM
http://purl.bioontology.org/ontology/SNOMEDCT/387003001 SNOMEDCT LOOM
http://purl.obolibrary.org/obo/DDO.owl#DDO_0004971 FASTO LOOM
http://purl.obolibrary.org/obo/DDO.owl#DDO_0004971 DDO LOOM
http://purl.obolibrary.org/obo/DDO.owl#DDO_0004971 DMTO LOOM
http://purl.bioontology.org/ontology/NDFRT/N0000148593 NDFRT LOOM
http://purl.bioontology.org/ontology/PDQ/CDR0000042265 PDQ LOOM
http://data.bnf.fr/ark:/12148/cb14456492g FAST-TOPICAL LOOM